Remove Containment Remove Development Remove Engineer Remove RNA
article thumbnail

Risk Assessment for use of Engineered Genetic Materials in Clinical Research

Advarra

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials. Why Does the IBC Need to do a Risk Assessment?

article thumbnail

Deep learning takes on synthetic biology

Scienmag

Computational algorithms enable identification and optimization of RNA-based tools for myriad applications DNA and RNA have been compared to “instruction manuals” containing the information needed for living “machines” to operate.

RNA 69
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Silent Mutations That Gave Coronavirus a Selective Advantage

XTalks

The answer may lie in the genetic code of the virus, which scientists at Duke University have found contains several silent mutations that affect protein folding. Related: Study Dispels Claim that COVID-19-Causing Coronavirus is Lab-Engineered. Moreover, Berrio says the changes likely affected the folding and function of viral RNA.

RNA 98
article thumbnail

A better tool for the job: Laser-based technique to elucidate the mysteries of exosomes

Scienmag

Undergraduate students explore a more efficient way to measure protein-containing vessels released by cells Credit: DGIST Despite our great progress in understanding various cellular mechanisms over the last decades, many of them remain unclear. The […].

article thumbnail

Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

The Pharma Data

Takeda will assume sole responsibility for further worldwide development and commercialization, and Ovid will no longer have any financial obligation to Takeda under the original collaboration agreement, including for milestone payments or any future development and commercialization costs.

article thumbnail

Targeting a human protein may stop Ebola virus in its tracks

The Pharma Data

Back in 2018, researchers tested a broad-spectrum antiviral candidate called remdesivir/VEKLURY, which acts as a nucleotide decoy to get incorporated into the viral RNA genome and stop viral polymerase. The major challenge in developing drugs directly against Ebola virus polymerase is that scientists have not solved its atomic structure. .”

Protein 52
article thumbnail

Biopharma Leaders Unite To Stand With Science

The Pharma Data

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.